Welcure Drugs & Pharmaceuticals has informed that the statement of Investor Grievances pursuant to Regulation 13 (3) of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 as provided by its Registrar and Transfer Agent - Skyline Financial Services for the quarter and half year ended 30th September, 2024 is enclosed.
The above information is a part of company’s filings submitted to BSE.